Innate Pharma SA (IPHA)

Every figure this model derived for IPHA, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 140,000 PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities 2025-12-31
cash 28,092,000 CashAndCashEquivalents 2025-12-31
current assets 46,710,000 CurrentAssets 2025-12-31
current liabilities 36,649,000 CurrentLiabilities 2025-12-31
equity -21,704,000 Equity 2025-12-31
interest expense 440,000 InterestExpense 2025-12-31
ocf -52,755,000 CashFlowsFromUsedInOperatingActivities 2025-12-31
revenue 2,787,000 RevenueFromContractsWithCustomers 2025-12-31
sbc 2,567,000 ExpenseFromSharebasedPaymentTransactionsWithEmployees 2025-12-31

The ratios

The figures themselves rather than their scores — what somebody looking up IPHA on one particular measure came for.

RatioValue
cash operating margin-1796.09
current ratio1.27
current ratio reported1.27
dilution pct10.54
fcf margin-1897.92
interest cover-122.75
operating margin-1937.85
revenue growth-77.92
revenue growth per share-80.03
rule of 40-2015.77
sbc pct revenue92.11

What to be careful about

What this model itself distrusts about IPHA's figures. Written by the derivation as it ran, not added afterwards.